Celcuity Inc. Unveils Presentation on Breakthrough Cancer Treatments Targeting PI3K/AKT/mTOR Pathway

Reuters

2025/08/04

<a href="https://laohu8.com/S/CELC">Celcuity Inc</a>. Unveils Presentation on Breakthrough Cancer Treatments Targeting PI3K/AKT/mTOR Pathway

Celcuity Inc. has released a corporate presentation highlighting their progress in cancer treatment, focusing on the PI3K/AKT/mTOR pathway. The presentation details the efficacy of gedatolisib in treating HR+/HER2- advanced breast cancer. Notably, the gedatolisib triplet and doublet therapies demonstrated significant improvement in median progression-free survival compared to fulvestrant alone. The company is currently enrolling patients for a Phase 3 study in first-line HR+/HER2- advanced breast cancer and conducting a Phase 1b/2 trial in second-line metastatic castration-resistant prostate cancer. Celcuity emphasizes the potential of PAM pathway inhibitors in oncology, targeting a large patient population in the US, Europe, and Japan. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2556386996"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556386996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556386996?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556386996","market":"nz","top_or_hot":-1,"title":"Celcuity Inc. Unveils Presentation on Breakthrough Cancer Treatments Targeting PI3K/AKT/mTOR Pathway","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a>. Unveils Presentation on Breakthrough Cancer Treatments Targeting PI3K/AKT/mTOR Pathway\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Celcuity Inc. has released a corporate presentation highlighting their progress in cancer treatment, focusing on the PI3K/AKT/mTOR pathway. The presentation details the efficacy of gedatolisib in treating HR+/HER2- advanced breast cancer. Notably, the gedatolisib triplet and doublet therapies demonstrated significant improvement in median progression-free survival compared to fulvestrant alone. The company is currently enrolling patients for a Phase 3 study in first-line HR+/HER2- advanced breast cancer and conducting a Phase 1b/2 trial in second-line metastatic castration-resistant prostate cancer. Celcuity emphasizes the potential of PAM pathway inhibitors in oncology, targeting a large patient population in the US, Europe, and Japan. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celcuity Inc. Unveils Presentation on Breakthrough Cancer Treatments Targeting PI3K/AKT/mTOR Pathway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelcuity Inc. Unveils Presentation on Breakthrough Cancer Treatments Targeting PI3K/AKT/mTOR Pathway\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-04 19:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a>. Unveils Presentation on Breakthrough Cancer Treatments Targeting PI3K/AKT/mTOR Pathway\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Celcuity Inc. has released a corporate presentation highlighting their progress in cancer treatment, focusing on the PI3K/AKT/mTOR pathway. The presentation details the efficacy of gedatolisib in treating HR+/HER2- advanced breast cancer. Notably, the gedatolisib triplet and doublet therapies demonstrated significant improvement in median progression-free survival compared to fulvestrant alone. The company is currently enrolling patients for a Phase 3 study in first-line HR+/HER2- advanced breast cancer and conducting a Phase 1b/2 trial in second-line metastatic castration-resistant prostate cancer. Celcuity emphasizes the potential of PAM pathway inhibitors in oncology, targeting a large patient population in the US, Europe, and Japan. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELC","symbol_name":"Celcuity Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL9S1GXv:1","article_id":"2556386996","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556386996","pubTimestamp":1754307324,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Celcuity Inc. has released a corporate presentation highlighting their progress in cancer treatment, focusing on the PI3K/AKT/mTOR pathway. The presentation details the efficacy of gedatolisib in treating HR+/HER2- advanced breast cancer. Notably, the gedatolisib triplet and doublet therapies demonstrated significant improvement in median progression-free survival compared to fulvestrant alone. The company is currently enrolling patients for a Phase 3 study in first-line HR+/HER2- advanced breast cancer and conducting a Phase 1b/2 trial in second-line metastatic castration-resistant prostate cancer. Celcuity emphasizes the potential of PAM pathway inhibitors in oncology, targeting a large patient population in the US, Europe, and Japan. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELC":"Celcuity Inc","BK4139":"生物科技"},"translate_title":"Celcuity Inc.推出针对PI3K/AKT/mTOR通路的突破性癌症治疗演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":0.9},"content_text":"Celcuity Inc. Unveils Presentation on Breakthrough Cancer Treatments Targeting PI3K/AKT/mTOR Pathway\n    \n\n        Celcuity Inc. has released a corporate presentation highlighting their progress in cancer treatment, focusing on the PI3K/AKT/mTOR pathway. The presentation details the efficacy of gedatolisib in treating HR+/HER2- advanced breast cancer. Notably, the gedatolisib triplet and doublet therapies demonstrated significant improvement in median progression-free survival compared to fulvestrant alone. The company is currently enrolling patients for a Phase 3 study in first-line HR+/HER2- advanced breast cancer and conducting a Phase 1b/2 trial in second-line metastatic castration-resistant prostate cancer. Celcuity emphasizes the potential of PAM pathway inhibitors in oncology, targeting a large patient population in the US, Europe, and Japan. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}